Polypid Ltd PYPD

$5.29 +0.04 (0.71%)

Valuation

Market cap
100,186,000
Revenue TTM
$0
Net income TTM
$-34,170,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
85,286
Avg volume
105,352
Day's range
$5.17 – $5.37
Shares out
19,083,000
Stochastic %K
100%
Beta
1.38
Analysts
Strong Sell
Price target
$11.75

Price

Company profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery...

Show more

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 7 4719 5700
Website
https://www.polypid.com
Address
18 Hasivim Street, Petah Tikva, Israel

Latest news